Platform|API|Archive|Contact

Humanexa SignalsPharmaceutical Intelligence

FDA
EMA
MHRA
PMDA
Health Canada

Phase I
Phase II
Phase III
Readouts
Enrollment Signals

Pipeline Tracking
Company Moves
Asset Intelligence
Landscape Reports

Pricing
Access
Commercial
Launch Tracking

Licensing
Acquisitions
Partnerships
Capital Raises

Strategy Catalysts Pricing

Humanexa Signals

Data-driven pharmaceutical intelligence for biotech investors, pharma operators, consultants, and intelligence teams.

Powered by Humanexa

Categories

Regulatory
Clinical
Competitive
Markets
M&A Watch
Strategy
Catalyst Tracker

Company

Pricing
Partner with us
Subscribe
Contact
Privacy

Subscribe to Humanexa Signals

Weekly intelligence for pharma decision-makers.

No paywall. No spam. Unsubscribe anytime.

© 2026 Humanexa Signals. All rights reserved.

Intelligence powered by the Humanexa engine.

Asset / Drug

baricitinib

Drug and asset intelligence for baricitinib with 5 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals: 3
Catalysts: 2
Stage: Development stage unavailable

Sponsor company

Recent signals(3)

ClinicalJuly 21, 2026

Eli Lilly's Baricitinib Evaluated for Safety in Pediatric sJIA Patients

Eli Lilly is conducting a study to assess the safety and efficacy of baricitinib in children with systemic juvenile idiopathic arthritis.

RegulatoryJuly 7, 2026

FDA Authorizes Baricitinib and Remdesivir Combination for COVID-19 Treatment

The FDA has granted emergency use authorization for baricitinib combined with remdesivir for treating COVID-19 in hospitalized patients.

ClinicalJune 21, 2026

Baricitinib Trial for Job Syndrome Patients with Lupus-Like Disease or Atopic Dermatitis

A clinical trial is evaluating the safety and tolerability of baricitinib in patients with Job syndrome who also have lupus-like disease or atopic dermatitis.

Upcoming milestones

No catalysts indexed for this entity yet.

Related catalysts(2)

Topline Data

— baricitinib

July 7, 2026 · N/A

Topline Data

— Baricitinib

June 21, 2026 · N/A

Indications

Infectious Disease →

Systemic Juvenile Idiopathic Arthritis →

Therapeutic areas

Infectious Disease →

Infectious Disease · COVID-19 →

Rheumatology →

Systemic Juvenile Idiopathic Arthritis →

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.